Four-Year safety check for promising sickle cell drug
Disease control
Not yet recruiting
This study aims to understand the long-term safety of a daily medication called pociredir for adults with sickle cell disease. It will follow 50 participants who previously benefited from the drug in an earlier study, monitoring them for up to 4 years. The main goal is to see if …
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC